[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental drug name: Carvativir 6 mg/ml diluted for oral solution. Qualitative and quantitative composition: Each ml contains 6mg of CARVATIVIR (2-Methyl-5-(1-methylethyl)-phenol modified) at 1% v/v. (Isothymol modified lipophilic GRAS). Pharmaceutical form: Oral solution (dispersion L/L). Dilute lipophilic aqueous solution of light or medium yellow. Excipients q.s: cis-9-octadecenoic acid with Squalene (99% v/v). Presentation: Carvativir (Modified Isothymol) comes in a 15 cc presentation in a plastic container; with label and sealed. Dosage and method of administration: The recommended dose of Carvativir in patients over 18 years of age and weighing at least 45 kg is: Five to fifteen loading drops of Carvativir 6mg/ml administered orally sublingually every 4 hours according to administration criteria. Control type and design Randomized; double-blind; multicenter study with blind evaluation of events; designed to compare the efficacy and safety of Isothymol modified with placebo in patients =18 years of age who meet the inclusion criteria. Drug administration scheme: Randomized and parallel (modified isothymol and placebo). Statistical design: Superiority. It will allow the detection of the difference between drug and placebo after parallel administration. Masking techniques The assigned treatment will not be known to the study subjects; the participating researchers and the evaluators of the criteria of study assessment. The placebo should contain the same technical specifications and physical appearance of modified Isothymol.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2547, "treatment_name": "Modified isothymol", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]